DDR-targeted therapies are emerging as promising strategies for treating breast cancer, particularly triple-negative breast cancer, wherein overexpression of DNA repair proteins, such as PARP1 and replication protein A, might alter the sensitivity to chemotherapy and DDR inhibitors (Lee et al., 2020). Here, PARP1 is linked to breast cancer.